Napo pharmaceuticals, a jaguar health family company, submits funding application to barda for development of np-300 drug candidate for cholera-related diarrhea

Funding for phase 1, 2, and 3 trials sought to develop np-300 to increase american preparedness and response time in event of exposure to cholera due to bioterrorism or advancement of cholera into us territories due to global warming cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium vibrio cholerae jaguar to present august 10th at emerging growth conference; individual and institutional investors as well as advisors, analysts, and members of the financial media are invited to attend jaguar's real-time interactive presentation san francisco, ca / accesswire / august 9, 2023 / napo pharmaceuticals inc. (napo), a jaguar health, inc. (nasdaq:jagx) family company, today announced that it has submitted a stage 1 funding application to the biomedical advanced research and development authority (barda) for development of np-300, the company's novel drug product candidate for the symptomatic relief and treatment of moderate-to-severe diarrhea, with or without concomitant antimicrobial therapy, from bacterial, viral and parasitic infections including vibrio cholerae, the bacterium that causes cholera. barda, part of the administration for strategic preparedness and response at the u.s. department of health and human services, supports advanced research and development of medical countermeasures and is a component of the public health emergency medical countermeasures enterprise (phemce).
JAGX Ratings Summary
JAGX Quant Ranking